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Umbilical cord blood (UCB) is an alternative graft source for
hematopoietic stem cell transplantation and has been shown
to yield results comparable to transplantation with other
stem cell sources. Donor lymphocyte infusion (DLI) is an
effective treatment for relapsed hematological malignancies
after hematopoietic stem cell transplantation. However, DLI
is not available after UCB transplantation.
In this study, in vitro cultured T-cells from the UCB graft
were explored as an alternative to conventional DLI. The
main aim was to study the safety of treatment with the
cultured UCB T-cells, as cell products prepared in this
particular manner has not been used before. We also wanted
to study potential beneﬁts of the treatment.
The cultured UCB T cells (UCB DLI) were given to four
patients with mixed chimerism (n ¼ 2), minimal residual
disease (n ¼ 1) and graft failure (n¼ 1). No adverse reactions
were seen at transfusion. Graft-versus-host disease (GVHD)
is a known risk in conventional DLI treatment. We thus
carefully assessed the included patients for signs of GVHD.
Three of the patients did not show any signs of GVHD after
treatment with UCB DLI. However, GVHD could not bewholly
excluded in the last patient. The symptoms were, however,
not consistently in temporal association with the treatment,
and the patient also had a severe adenovirus infection that
could explain the symptoms. In the patient with minimal
residual disease, the malignant cell clone was detectable
shortly before infusion but undetectable at treatment and for
3 months after infusion. In one patient with mixed chi-
merism, the percentage of recipient cells decreased in tem-
poral association with UCB DLI treatment.
In summary, we saw no certain adverse effects of
treatment with UCB DLI. Events that could indicate possible
beneﬁts were seen but with no certain causal association
with the treatment.171
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Introduction: Decidual stromalcells (DSCs) isolated fromfetal
membranes of term placentas are easily expanded and highly
immunosuppressive in vitro. DSCs have a high expression ofintegrins that are of importance for homing to damaged tissue.
In thepresent study,we introduceDSCsasa cellular therapy for
chronic Graft-versus-Host Disease (cGvHD).
Patients and Methods: Three patients (1 (ALL), 2 (AML), and
3 (CML)) with severe extensive cGvHD were treated with
DSCs (1-2.8 x 106 cells/kg). Patients 1 and 2 received two
infusions and patient 3 received one dose. One third of DSCs
administered to patient 1 and 2 were labelled with 111Indium
and the in vivo-distribution was tracked for 48h. Blood
samples were obtained before and up to 4-10 weeks after the
ﬁrst infusion. Samples were analyzed by ﬂow cytometry and
luminex.
Results: All patients had cGVHD of skin, liver and obstructive
bronchiolitis. Patients 1 and 2 are regarded as partial re-
sponders (PR) and patient 3 as a non-responder (NR).
Response was evaluated according to the NIH guidelines for
diagnosing cGvHD.
Patients receiving 111In-DSCs showed the same distribu-
tion pattern of the isotope over time. The isotopewas initially
located in the lungs, followed by dissemination to liver and
spleen.
The ﬂow cytometry and luminex data are presented as the
median frequency of data from all time points for each pa-
tient. Patient 3 had high frequencies of HLA-DR+ cells within
the CD3+CD4+ cell population (Th) (median 72.9%, range
72.7-73.3%). The corresponding proportions in patients 1 and
2 were 21.5% (17.6-21.9) and 36.5% (25.8-50-8), respectively.
Among CD3+CD8+cells (Tc), the frequency of HLA-DR-
expression was 33.6% (30.9-37.5), 60.5% (56.7-68.1) and
80.6% (70.8-83.8) for patient 1, 2, and 3, respectively.
The percentage of Th-cells with a naïve (CD45RA+CCR7+)
phenotype was 4.8% (3.6-6.3) in patient 3, but 24.4% (4.3-
24.4) and 25.1% (11.2-26.3) in patient 1 and 2, respectively.
The proportion of terminally differentiated (CD45RA-CCR7+)
Th-cells was 2.3% (2.1-2.6), 7.4% (2.4-8.7) and 12.7% (10.9-
23.2) in patients 1, 2, and 3, respectively.
The frequency of Tregs (CD4+CD25highCD127low/-) was
11.5% (8.63-15.9) for patient 3, whereas they were 6.4%
(4.8-6.5) and 3.3% (2.5-4.8) for patient 1 and 2, respectively.
Patient 3 had the highest proportion Th-cells with a
Th17 (CD45RA-CXCR3-CCR4+CCR6+), Th1/Th17 (CD45RA-
CXCR3+CCR4-CCR6+) and Th2 phenotype (CD45RA-CCR4+
CXCR3-CCR6-). Patient 3 also had the highest median plasma
concentrations of IL-17, IL-4 and IFN-g.
Discussion: DSCs are safe to infuse with no adverse effects.
We determined how stromal cells are distributed in vivo
following infusion in a GvHD setting. The data also support
that the non-responder had a more activated/exhausted
immune system than the partial responders. This study may
provide a basis for further controlled investigations into use
of DSCs as a treatment for severe cGvHD.172
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Peripheral blood progenitor cell collection (PBPC) is a routine
procedure in auto-HCT recipient and allo-HCT donors.
Spectra Optia is a next generation apheresis platform
following Cobe Spectra. Increasing the efﬁciency of PBPC
Table 1
Comparison of MNC collections on Cobe Spectra and Spectra Optia.
Autologous Allogeneic
Cobe Spectra (n¼71) Spectra Optia (n¼26) p Cobe Spectra (n¼21) Spectra Optia (n¼8) p
Patient weight (kg) 89.2 [76.2;99.8]1 86.1 [63.4;112.8] 0.882 82.9 [67.1;89.7] 81.4 [76.1;115.8] 0.55
Pre WBC (x106/mL) 48.5 [33.0;70.3] 60.2 [51.6;71.1] 0.16 61.2 [51.2;69.1] 43.9 [43.1;52.3] 0.030
Pre CD34 (cells/ul) 75.0 [42.0;140.0] 104.0 [42.0;147.0] 0.28 114.0 [69.0;147.0] 65.5 [40.0;217.5] 0.42
W B processed (L) 27.4 [23.5;30.8] 16.8 [14.6;18.7] <0.001 22.0 [19.3;27.2] 16.3 [15.2;18.2] <0.001
Product Hct (%) 2.1 [1.7;3.4] 1.3 [1.0;2.1] <0.001 2.4 [1.9;3.1] 1.2 [1.1;1.5] <0.001
CD34+ (x106/kg) 6.2 [3.2;11.2] 10.2 [4.4;15.4] 0.059 8.1 [6.2;9.7] 6.8 [3.7;12.0] 0.92
CD34 CE2 (%) 31.2 [21.5;38.5] 50.1 [42.3;54.7] <0.001 24.4 [19.6;29.3] 44.3 [37.8;50.6] <0.001
MNC CE2 (%) 34.3 [25.2;49.2] 73.7 [50.6;81.2] <0.001 33.2 [27.0;47.2] 65.1 [61.5;82.6] <0.001
1 Results are depicted as median [IQR].
2 p values were calculated with Mann-Whitney U test.
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processed blood while acquiring the targeted CD34+ cell
dose. Retrospective analysis of mononuclear cell (MNC) col-
lections was performed in 61 auto-HCT candidates and 28
donors for allo-HCT using Cobe Spectra or Spectra Optia. The
target CD34+ cell dose was 10x106/kg for multiple myeloma
and 5-7x106/kg for lymphomas. For healthy allo-HCT donors
the target depended on the recipient diagnosis. Collection
efﬁciency was evaluated as [total number CD34+ cells in
product/(peripheral blood CD34+ cell count x blood volume
processed)]. Pre-apheresis WBC and CD34+ measurements
were not signiﬁcantly different. The implementation of
Spectra Optia in auto-HCT recipients increased the CD34+
CE2 from 31.2% to 50.1% compared to Cobe Spectra, and from
24.4% to 41.3% in allo-HCT donors. This translated in signiﬁ-
cantly lower volumes of blood processed to obtain an equal
CD34+ dose (Table I). In addition, MNC CE2 signiﬁcantly
increased and median Hct in the product decreased on
Spectra Optia, indicating a higher purity of the collected
product. Moreover, we witnessed an increase of the CD34+
collection efﬁciency on Spectra Optia in years 2014 versus
2013, indicating a learning curve was inherent to the
implementation. Our study shows that the integration of
MNC collections on Spectra Optia greatly increased efﬁciency
of CD34+ cell collection in comparison to the Cobe Spectra.
Consequently, lower blood volumes were processed to
obtain equal to better CD34+ cell dose. These results invite to
assess further the impact of implementation of Spectra Optia
on the number of collection days.173
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nocompetent host express the type II latency antigens LMP1
and LMP2 which can serve as potential targets for immu-
notherapy. For many patients with chronic active EBV
(CAEBV) and/or relapsed EBV+ Non Hodgkin Lymphoma
(NHL) or Hodgkin Lymphoma (HL) the only potential cura-
tive option is allogeneic hematopoietic stem cell transplant
(allo-HSCT). However, relapse rates remain high (>50%) and
the risk of inducing graft versus host disease (GvHD) after
DLI limits the broad application of this approach. We hy-
pothesized that the administration of donor-derived cyto-
toxic T lymphocytes (CTLs) directed to LMP1/2 (LMP-CTL)
would rapidly restore LMP-speciﬁc T-cell immunity and
prevent relapse in these high-risk patients without
increasing the incidence of GvHD. LMP-CTLs were expanded
using donor monocytes and EBV transformed lympho-
blastoid cell lines, transduced with an adenoviral vector
encoding either LMP2 (n¼4) or DLMP1 and LMP2 (n¼11).
Characterization of CTL lines at cryopreservation revealed
CD4+ and CD8+ cells which were predominantly effector
and effector memory phenotype. CTL lines had LMP2
(+/-LMP1) speciﬁc activity as determined by ELISPOT and
cytotoxicity assays. Fifteen patients (n¼5 HL, n¼4 B-cell
CAEBV/NHL, n¼6 T-cell CAEBV/NHL) received 2 infusions of
CTLs (dose range: 0.4-3x10e8/m2) approximately 100 days
post HSCT. No immediate toxicities related to CTL infusions
were observed. Infusion of LMP-CTLs resulted in a
maximum 2.5 fold increase in the frequency of LMPs pre-
cursors as detected by IFNg eliSPOT assay. No patient
developed de novo GVHD post CTLs. GVHD was seen in 4
patients with a pre-existing history (1 patient with DLBCL
experienced grade II skin GvHD controlled with steroids, 2
patients (1 NK-T and 1 HL) showed signs of grade I GvHD
promptly controlled with steroids. One patient with DLBCL
developed grade III GvHD after weaning immune suppres-
sion and subsequently developed sepsis and died 10 months
after an HLA matched-unrelated HSCT). 13 patients were in
remission at the time of CTL infusion and 12/13 of these
patients remained in remission for a median of 30 months
post CTLs (range 6-90 months). One patient with NK/T cell
NHL relapsed 6 months post CTLs and died of progressive
disease. Two patients (1HL and 1 T-cell CAEBV) received
CTLs for relapsed disease after HSCT and both died of dis-
ease. Disease progression in the patient with HL, was likely
due to immune-escape since tumor biopsies obtained post
CTL were EBV-negative. In conclusion, donor-derived LMP-
CTLs seem to be well tolerated in high-risk patients with
CAEBV and/or EBV+ lymphoma post HSCT. Furthermore, the
use of donor-derived tumor-directed T-cells as adjuvant
therapy post HSCT may restore LMP-speciﬁc T-cell immu-
nity and prevent relapse in this high-risk patient pop-
ulation.
